Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review

Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders influenced by microbial, environmental, genetic, and immune factors. The introduction of biological agents has transformed IBD therapy, improving symptoms, reducing complications, and enhancing patients’ quality of life. However,...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 26; no. 4; p. 1760
Main Authors Ballesta-López, Octavio, Gil-Candel, Mayte, Centelles-Oria, María, Megías-Vericat, Juan Eduardo, Solana-Altabella, Antonio, Ribes-Artero, Hugo, Nos-Mateu, Pilar, García-Pellicer, Javier, Poveda-Andrés, José Luis
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 19.02.2025
MDPI
Subjects
Analysis
Biological Factors - therapeutic use
Clinical outcomes
Crohn's disease
Diseases
Ethnicity
Genes
Genetic markers
Genotype & phenotype
Humans
Inflammatory bowel disease
Inflammatory Bowel Diseases - drug therapy
Inflammatory Bowel Diseases - genetics
Kinases
Medical research
Medical Subject Headings-MeSH
Pharmacogenetics
Pharmacogenetics - methods
Polymorphism
Precision Medicine
Review
Spain
Systematic review
Tofacitinib
Toxicity
Treatment Outcome
Tumor necrosis factor-TNF
Spain
vedolizumab
ustekinumab
infliximab
polymorphism
ulcerative colitis
adalimumab
inflammatory bowel disease
Crohn’s disease
Online AccessGet full text
ISSN1422-0067
1661-6596
1422-0067
DOI10.3390/ijms26041760

Cover

Abstract Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders influenced by microbial, environmental, genetic, and immune factors. The introduction of biological agents has transformed IBD therapy, improving symptoms, reducing complications, and enhancing patients’ quality of life. However, approximately 30% of patients exhibit primary non-response, and 50% experience a loss of response over time. Genetic and non-genetic factors contribute to variability in treatment outcomes. This systematic review aims to thoroughly analyze and assess existing studies exploring the relationships between genetic variations and individual responses to biologic drugs, in order to identify genetic markers that are predictive of treatment efficacy, risk of adverse effects, or drug toxicity, thereby informing clinical practice and guiding future research. PubMed and EMBASE papers were reviewed by three independent reviewers according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] guidelines. Of the 883 records screened, 99 met the inclusion criteria. The findings of this review represent an initial step toward personalized medicine in IBD, with the potential to improve clinical outcomes in biological therapy.
AbstractList Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders influenced by microbial, environmental, genetic, and immune factors. The introduction of biological agents has transformed IBD therapy, improving symptoms, reducing complications, and enhancing patients' quality of life. However, approximately 30% of patients exhibit primary non-response, and 50% experience a loss of response over time. Genetic and non-genetic factors contribute to variability in treatment outcomes. This systematic review aims to thoroughly analyze and assess existing studies exploring the relationships between genetic variations and individual responses to biologic drugs, in order to identify genetic markers that are predictive of treatment efficacy, risk of adverse effects, or drug toxicity, thereby informing clinical practice and guiding future research. PubMed and EMBASE papers were reviewed by three independent reviewers according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] guidelines. Of the 883 records screened, 99 met the inclusion criteria. The findings of this review represent an initial step toward personalized medicine in IBD, with the potential to improve clinical outcomes in biological therapy.Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders influenced by microbial, environmental, genetic, and immune factors. The introduction of biological agents has transformed IBD therapy, improving symptoms, reducing complications, and enhancing patients' quality of life. However, approximately 30% of patients exhibit primary non-response, and 50% experience a loss of response over time. Genetic and non-genetic factors contribute to variability in treatment outcomes. This systematic review aims to thoroughly analyze and assess existing studies exploring the relationships between genetic variations and individual responses to biologic drugs, in order to identify genetic markers that are predictive of treatment efficacy, risk of adverse effects, or drug toxicity, thereby informing clinical practice and guiding future research. PubMed and EMBASE papers were reviewed by three independent reviewers according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] guidelines. Of the 883 records screened, 99 met the inclusion criteria. The findings of this review represent an initial step toward personalized medicine in IBD, with the potential to improve clinical outcomes in biological therapy.
Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders influenced by microbial, environmental, genetic, and immune factors. The introduction of biological agents has transformed IBD therapy, improving symptoms, reducing complications, and enhancing patients’ quality of life. However, approximately 30% of patients exhibit primary non-response, and 50% experience a loss of response over time. Genetic and non-genetic factors contribute to variability in treatment outcomes. This systematic review aims to thoroughly analyze and assess existing studies exploring the relationships between genetic variations and individual responses to biologic drugs, in order to identify genetic markers that are predictive of treatment efficacy, risk of adverse effects, or drug toxicity, thereby informing clinical practice and guiding future research. PubMed and EMBASE papers were reviewed by three independent reviewers according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] guidelines. Of the 883 records screened, 99 met the inclusion criteria. The findings of this review represent an initial step toward personalized medicine in IBD, with the potential to improve clinical outcomes in biological therapy.
Audience Academic
Author Gil-Candel, Mayte
Nos-Mateu, Pilar
Megías-Vericat, Juan Eduardo
Centelles-Oria, María
Ribes-Artero, Hugo
Solana-Altabella, Antonio
García-Pellicer, Javier
Poveda-Andrés, José Luis
Ballesta-López, Octavio
AuthorAffiliation 2 Accredited Research Group on Pharmacy, Instituto de Investigación Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain
4 Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Universitari i Politècnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain
1 Pharmacy Department, Hospital Universitari i Politècnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain; ballesta_oct@gva.es (O.B.-L.)
3 Accredited Research Group on Hematology, Instituto de Investigación Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain
5 Management Department, Hospital Universitari i Politècnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain
AuthorAffiliation_xml – name: 5 Management Department, Hospital Universitari i Politècnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain
– name: 2 Accredited Research Group on Pharmacy, Instituto de Investigación Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain
– name: 3 Accredited Research Group on Hematology, Instituto de Investigación Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain
– name: 1 Pharmacy Department, Hospital Universitari i Politècnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain; ballesta_oct@gva.es (O.B.-L.)
– name: 4 Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Universitari i Politècnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain
Author_xml – sequence: 1
  givenname: Octavio
  orcidid: 0000-0002-5444-5836
  surname: Ballesta-López
  fullname: Ballesta-López, Octavio
– sequence: 2
  givenname: Mayte
  orcidid: 0000-0002-7398-8350
  surname: Gil-Candel
  fullname: Gil-Candel, Mayte
– sequence: 3
  givenname: María
  orcidid: 0000-0003-2902-6178
  surname: Centelles-Oria
  fullname: Centelles-Oria, María
– sequence: 4
  givenname: Juan Eduardo
  orcidid: 0000-0002-0369-5341
  surname: Megías-Vericat
  fullname: Megías-Vericat, Juan Eduardo
– sequence: 5
  givenname: Antonio
  orcidid: 0000-0002-8804-3878
  surname: Solana-Altabella
  fullname: Solana-Altabella, Antonio
– sequence: 6
  givenname: Hugo
  orcidid: 0009-0009-6038-8151
  surname: Ribes-Artero
  fullname: Ribes-Artero, Hugo
– sequence: 7
  givenname: Pilar
  orcidid: 0000-0002-6619-1511
  surname: Nos-Mateu
  fullname: Nos-Mateu, Pilar
– sequence: 8
  givenname: Javier
  surname: García-Pellicer
  fullname: García-Pellicer, Javier
– sequence: 9
  givenname: José Luis
  orcidid: 0000-0003-1800-6198
  surname: Poveda-Andrés
  fullname: Poveda-Andrés, José Luis
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40004223$$D View this record in MEDLINE/PubMed
BookMark eNptkktvGyEUhVGVqnm0u64rpG66qJPLwAwz3VROmqSRIrXqY40w3HGwGHBhnMj_vjivOlXEAsT5OJeje_fJTogBCXnL4JDzDo7cYshVA4LJBl6QPSaqagLQyJ2t8y7Zz3kBUPGq7l6RXQEAReN7xH6_0mnQJs4x4OhMpi7QH5iXMWSkY6THLvo4d0Z7Oi3MeAtchN7rYdBjTGt6HG_Q0y8uo874iU7pz3UesYjOFKdrhzevycte-4xv7vcD8vvs9NfJ18nlt_OLk-nlxAgux8msqlsmBLBWs7YG1nDL0Bjd8F6grdtGYG1bPtNSAucWuLTQVrxHIe0MpOEH5POd73I1G9Ca8t2kvVomN-i0VlE79VQJ7krN47VipV4tpCgOH-4dUvyzwjyqwWWD3uuAcZUVZ5Jx2XWCFfT9f-girlIo-W4pqGou4B811x6VC30shc3GVE3bqpO14LDxOnyGKsvi4Ezpd-_K_ZMH77aTPkZ8aGwBPt4BJsWcE_aPCAO1mRu1PTf8L_GTs2U
Cites_doi 10.1038/ajg.2011.60
10.1097/MIB.0000000000001150
10.1002/ibd.21174
10.1016/j.phrs.2023.106859
10.1007/s40262-014-0225-3
10.3390/genes14020445
10.1371/journal.pone.0204632
10.3390/biomedicines9121748
10.1097/01.fpc.0000204993.91806.b1
10.1155/2015/318207
10.1038/s41598-021-84909-z
10.1007/s00251-013-0679-8
10.1186/s12964-024-01533-w
10.1016/j.humimm.2013.09.017
10.1016/S0016-5085(21)00918-5
10.3390/ijms19082244
10.1093/gastro/goz056
10.1053/j.gastro.2019.09.041
10.4292/wjgpt.v8.i4.193
10.1111/jgh.14652
10.1016/j.mrfmmm.2006.09.002
10.1038/ajg.2016.306
10.1097/FPC.0000000000000471
10.3390/ijms23136966
10.1016/S0016-5085(17)31514-7
10.1016/j.cytogfr.2023.07.001
10.1002/jgh3.12398
10.1111/cts.13075
10.3390/ijms25073717
10.14309/01.ajg.0000776332.13982.cb
10.1186/s12967-019-02174-1
10.1007/s00228-012-1389-0
10.1136/bmj.n71
10.3390/jcm12227132
10.1093/ibd/izy083
10.1093/gastro/goaa070
10.3390/ijms25115793
10.1093/ecco-jcc/jjz017
10.1080/17474124.2018.1494573
10.1097/01.fpc.0000230117.26581.a4
10.1093/ecco-jcc/jjab076.390
10.1136/ard.58.2008.i114
10.1016/S0016-5085(22)61892-4
10.3389/fimmu.2024.1342477
10.3390/genes14020452
10.3748/wjg.v20.i13.3609
10.1007/s00535-006-1995-7
10.1038/s41397-019-0090-4
10.1016/j.biopha.2023.114225
10.14309/01.ajg.0000777364.76967.26
10.1111/iji.12059
10.1089/gtmb.2015.0036
10.1111/jgh.14696
10.1007/s10528-016-9734-0
10.3390/pharmaceutics13010077
10.3389/fphar.2023.1096816
10.3389/fphar.2020.01207
10.7150/ijms.22812
10.1093/ecco-jcc/jjaa053
10.1053/gast.2001.23966
10.1007/s00535-014-1020-5
10.1152/physiol.00025.2014
10.1038/tpj.2016.84
10.1080/gas.37.7.818.824
10.1111/j.1365-2036.2004.01946.x
10.1038/tpj.2014.19
10.3748/wjg.v23.i27.4958
10.1053/gast.2002.34172
10.1111/j.1365-2036.2008.03630.x
10.1111/j.1365-2036.2005.02635.x
10.1159/000444479
10.1016/j.phrs.2019.104478
10.1111/j.1365-2036.2005.02701.x
10.1038/ajg.2016.408
10.1111/apt.15563
10.1093/ibd/izac259
10.5152/tjg.2020.19436
10.1097/MPG.0000000000002840
10.1177/1756283X16638833
10.1097/00008571-200210000-00002
10.1111/bcp.14400
10.3390/ijms24021797
10.1038/nrgastro.2015.34
10.3748/wjg.v11.i8.1187
10.1155/2015/416838
10.3390/genes12060866
10.1111/apt.12010
10.1093/ibd/izac188
10.1111/j.1365-2036.2004.01871.x
10.1097/01.fpc.0000230421.12844.fd
10.1089/omi.2016.0005
10.1093/ecco-jcc/jjz203.839
10.3389/fped.2021.744599
10.1038/s41397-023-00304-z
10.1097/01.fpc.0000182776.57437.d8
10.1111/1751-2980.12677
10.1097/FPC.0b013e32832a06bf
10.2217/pgs.14.172
10.1186/s12967-017-1355-9
10.1007/s10620-011-1977-3
10.1080/00365520601101559
10.1111/apt.15187
10.3748/wjg.v18.i36.5058
10.1093/ibd/izz059
ContentType Journal Article
Copyright COPYRIGHT 2025 MDPI AG
2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025 by the authors. 2025
Copyright_xml – notice: COPYRIGHT 2025 MDPI AG
– notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025 by the authors. 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.3390/ijms26041760
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
CrossRef
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1422-0067
ExternalDocumentID PMC11855474
A829754301
40004223
10_3390_ijms26041760
Genre Systematic Review
Journal Article
GeographicLocations Spain
GeographicLocations_xml – name: Spain
GroupedDBID ---
29J
2WC
53G
5GY
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
8G5
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
AEAQA
AENEX
AFKRA
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
D1I
DIK
DU5
DWQXO
E3Z
EBD
EBS
EJD
ESX
F5P
FRP
FYUFA
GNUQQ
GUQSH
GX1
HH5
HMCUK
HYE
IAO
IHR
ITC
KQ8
LK8
M1P
M2O
M48
MODMG
O5R
O5S
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RPM
TR2
TUS
UKHRP
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7XB
8FK
K9.
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
ESTFP
PUEGO
5PM
ID FETCH-LOGICAL-c437t-b258144018a1850163d1ecca63f4ed5864e5d83ba77033d037d0823fe47db07c3
IEDL.DBID M48
ISSN 1422-0067
1661-6596
IngestDate Thu Aug 21 18:27:39 EDT 2025
Mon Sep 08 17:04:54 EDT 2025
Fri Jul 25 21:33:32 EDT 2025
Tue Jun 17 21:59:00 EDT 2025
Tue Jun 10 21:09:01 EDT 2025
Wed Jul 30 01:49:41 EDT 2025
Tue Jul 01 05:42:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords vedolizumab
ustekinumab
infliximab
polymorphism
ulcerative colitis
adalimumab
inflammatory bowel disease
Crohn’s disease
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c437t-b258144018a1850163d1ecca63f4ed5864e5d83ba77033d037d0823fe47db07c3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Undefined-1
ObjectType-Review-4
content type line 23
ORCID 0000-0002-7398-8350
0000-0002-6619-1511
0000-0002-0369-5341
0000-0003-1800-6198
0000-0003-2902-6178
0009-0009-6038-8151
0000-0002-5444-5836
0000-0002-8804-3878
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/ijms26041760
PMID 40004223
PQID 3171025340
PQPubID 2032341
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_11855474
proquest_miscellaneous_3171379941
proquest_journals_3171025340
gale_infotracmisc_A829754301
gale_infotracacademiconefile_A829754301
pubmed_primary_40004223
crossref_primary_10_3390_ijms26041760
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20250219
PublicationDateYYYYMMDD 2025-02-19
PublicationDate_xml – month: 2
  year: 2025
  text: 20250219
  day: 19
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle International journal of molecular sciences
PublicationTitleAlternate Int J Mol Sci
PublicationYear 2025
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Velasco (ref_35) 2023; 194
Kopylov (ref_11) 2016; 9
Sazonovs (ref_43) 2020; 158
Liu (ref_99) 2024; 22
Louis (ref_57) 2006; 16
Campillo (ref_89) 2014; 41
Rapti (ref_102) 2015; 19
ref_13
Louis (ref_114) 2002; 37
ref_10
Liu (ref_12) 2023; 71–72
Wang (ref_78) 2019; 13
Mascheretti (ref_112) 2002; 12
Pedrero (ref_30) 2013; 69
Willot (ref_104) 2006; 16
Bank (ref_18) 2014; 14
Guardiola (ref_76) 2016; 10
Matsukura (ref_90) 2008; 27
Billioud (ref_9) 2011; 106
ref_25
Lu (ref_106) 2012; 18
Aterido (ref_53) 2019; 19
Moroi (ref_58) 2013; 65
ref_27
Chande (ref_3) 2015; 10
Wang (ref_54) 2021; 116
Ananthakrishnan (ref_1) 2015; 12
ref_70
Zhu (ref_52) 2017; 152
ref_75
Taylor (ref_80) 2001; 120
Koder (ref_17) 2015; 16
Bossacoma (ref_19) 2020; 71
Zhang (ref_24) 2021; 9
Louis (ref_56) 2004; 19
Spencer (ref_105) 2021; 116
Vermeire (ref_113) 2002; 123
Garrote (ref_69) 2023; 29
Naviglio (ref_15) 2018; 12
Berg (ref_8) 2019; 25
Urcelay (ref_72) 2005; 11
Wilson (ref_45) 2020; 51
(ref_6) 1999; 58
ref_88
Bank (ref_73) 2018; 18
ref_85
Bossacoma (ref_32) 2019; 68
Burke (ref_33) 2018; 24
Sands (ref_14) 2007; 42
Papaconstantinou (ref_111) 2017; 8
Fischer (ref_100) 2007; 42
Niess (ref_84) 2012; 57
Smithberger (ref_92) 2014; 62
Ozeki (ref_79) 2006; 602
Perera (ref_81) 2010; 87
Tang (ref_36) 2020; 8
ref_55
Dorrington (ref_4) 2020; 14
Zuraszek (ref_26) 2023; 133
Serra (ref_67) 2020; 14
Yoon (ref_48) 2017; 23
ref_61
Vermeire (ref_107) 2009; 19
Barber (ref_31) 2016; 111
Lobato (ref_34) 2019; 149
Medrano (ref_64) 2015; 2015
Tomita (ref_60) 2010; 57
Dideberg (ref_101) 2006; 16
Wang (ref_5) 2016; 4
Page (ref_16) 2021; 372
Billiet (ref_62) 2016; 111
Palmieri (ref_109) 2005; 22
Medrano (ref_21) 2014; 75
Endo (ref_93) 2020; 4
Claes (ref_98) 2015; 30
Dideberg (ref_108) 2006; 16
Mascheretti (ref_115) 2004; 18
Juanola (ref_83) 2015; 50
Ioannou (ref_42) 2021; 160
Demir (ref_96) 2020; 31
Bank (ref_20) 2019; 49
ref_117
Spalinger (ref_86) 2016; 93
ref_116
Repnik (ref_51) 2019; 27
Choi (ref_63) 2023; 29
ref_118
Repnik (ref_66) 2016; 54
Dubinsky (ref_23) 2010; 16
Kumar (ref_2) 2019; 17
Papamichael (ref_97) 2011; 24
ref_110
Pierik (ref_91) 2004; 20
ref_39
Dezelak (ref_50) 2016; 20
Spencer (ref_71) 2022; 162
Segarra (ref_82) 2021; 87
Park (ref_94) 2019; 34
Ouburg (ref_103) 2010; 102
Geiss (ref_37) 2018; 19
Curci (ref_38) 2021; 14
Ternant (ref_59) 2015; 54
Netz (ref_29) 2017; 23
ref_47
Repnik (ref_74) 2019; 26
ref_44
Jung (ref_65) 2019; 34
Stavrou (ref_87) 2022; 32
Hlavaty (ref_28) 2005; 22
ref_41
Cheli (ref_46) 2023; 23
Pedregosa (ref_40) 2018; 15
Thomas (ref_95) 2014; 20
Nuij (ref_49) 2017; 15
Santacana (ref_77) 2016; 23
Marin (ref_68) 2021; 15
Steenholdt (ref_22) 2012; 36
ref_7
References_xml – volume: 106
  start-page: 674
  year: 2011
  ident: ref_9
  article-title: Loss of Response and Need for Adalimumab Dose Intensification in Crohn’s Disease: A Systematic Review
  publication-title: Am. J. Gastroenterol.
  doi: 10.1038/ajg.2011.60
– volume: 23
  start-page: 1382
  year: 2017
  ident: ref_48
  article-title: Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD
  publication-title: Inflamm. Bowel Dis.
  doi: 10.1097/MIB.0000000000001150
– volume: 16
  start-page: 1357
  year: 2010
  ident: ref_23
  article-title: Genome Wide Association (GWA) Predictors of Anti-TNFalpha Therapeutic Responsiveness in Pediatric Inflammatory Bowel Disease
  publication-title: Inflamm. Bowel Dis.
  doi: 10.1002/ibd.21174
– volume: 194
  start-page: 106859
  year: 2023
  ident: ref_35
  article-title: Polymorphisms Indicating Risk of Inflammatory Bowel Disease or Antigenicity to Anti-TNF Drugs as Biomarkers of Response in Children
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2023.106859
– volume: 54
  start-page: 551
  year: 2015
  ident: ref_59
  article-title: Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease
  publication-title: Clin. Pharmacokinet.
  doi: 10.1007/s40262-014-0225-3
– ident: ref_110
  doi: 10.3390/genes14020445
– ident: ref_88
  doi: 10.1371/journal.pone.0204632
– volume: 27
  start-page: 1670
  year: 2019
  ident: ref_51
  article-title: Missense Variant Rs3740691 in Gene ARFGAP2 Predicts Short-Term Nonresponse to Anti-TNF Inhibitor Adalimumab in Crohn’s Disease Patients
  publication-title: Eur. J. Hum. Genet.
– volume: 57
  start-page: 535
  year: 2010
  ident: ref_60
  article-title: Association between Tumor Necrosis Factor-Alpha and Fc-Gamma Receptor Polymorphisms with Infliximab in Crohn’s Disease
  publication-title: Hepatogastroenterology
– ident: ref_117
  doi: 10.3390/biomedicines9121748
– volume: 16
  start-page: 369
  year: 2006
  ident: ref_108
  article-title: Lymphotoxin Alpha Gene in Crohn’s Disease Patients: Absence of Implication in the Response to Infliximab in a Large Cohort Study
  publication-title: Pharmacogenet. Genom.
  doi: 10.1097/01.fpc.0000204993.91806.b1
– volume: 2015
  start-page: 318207
  year: 2015
  ident: ref_64
  article-title: Response to Infliximab in Crohn’s Disease: Genetic Analysis Supporting Expression Profile
  publication-title: Mediators Inflamm.
  doi: 10.1155/2015/318207
– ident: ref_55
  doi: 10.1038/s41598-021-84909-z
– volume: 65
  start-page: 265
  year: 2013
  ident: ref_58
  article-title: FCGR3A-158 Polymorphism Influences the Biological Response to Infliximab in Crohn’s Disease through Affecting the ADCC Activity
  publication-title: Immunogenetics
  doi: 10.1007/s00251-013-0679-8
– volume: 22
  start-page: 159
  year: 2024
  ident: ref_99
  article-title: Role of the NF-kB Signalling Pathway in Heterotopic Ossification: Biological and Therapeutic Significance
  publication-title: Cell Commun. Signal. CCS
  doi: 10.1186/s12964-024-01533-w
– volume: 75
  start-page: 71
  year: 2014
  ident: ref_21
  article-title: Role of TNFRSF1B Polymorphisms in the Response of Crohn’s Disease Patients to Infliximab
  publication-title: Hum. Immunol.
  doi: 10.1016/j.humimm.2013.09.017
– volume: 160
  start-page: S-72
  year: 2021
  ident: ref_42
  article-title: Hispanic IBD patients with HLA-DQA1*05 have higher rates of anti-TNF immunogenicity compared to non-carriers
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(21)00918-5
– ident: ref_10
  doi: 10.3390/ijms19082244
– volume: 8
  start-page: 367
  year: 2020
  ident: ref_36
  article-title: Association of Polymorphisms in C1orf106, IL1RN, and IL10 with Post-Induction Infliximab Trough Level in Crohn’s Disease Patients
  publication-title: Gastroenterol. Rep. Oxf.
  doi: 10.1093/gastro/goz056
– volume: 158
  start-page: 189
  year: 2020
  ident: ref_43
  article-title: HLA-DQA1*05 Carriage Associated with Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients with Crohn’s Disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2019.09.041
– volume: 8
  start-page: 193
  year: 2017
  ident: ref_111
  article-title: Association of miR-146 Rs2910164, miR-196a Rs11614913, miR-221 Rs113054794 and miR-224 Rs188519172 Polymorphisms with Anti-TNF Treatment Response in a Greek Population with Crohn’s Disease
  publication-title: World J. Gastrointest. Pharmacol. Ther.
  doi: 10.4292/wjgpt.v8.i4.193
– volume: 34
  start-page: 1727
  year: 2019
  ident: ref_65
  article-title: ZNF133 Is Associated with Infliximab Responsiveness in Patients with Inflammatory Bowel Diseases
  publication-title: J. Gastroenterol. Hepatol.
  doi: 10.1111/jgh.14652
– volume: 602
  start-page: 170
  year: 2006
  ident: ref_79
  article-title: Analysis of Linkage between Lymphotoxin Alpha Haplotype and Polymorphisms in 5’-Flanking Region of Tumor Necrosis Factor Alpha Gene Associated with Efficacy of Infliximab for Crohn’s Disease Patients
  publication-title: Mutat. Res.
  doi: 10.1016/j.mrfmmm.2006.09.002
– volume: 111
  start-page: 1438
  year: 2016
  ident: ref_62
  article-title: A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease
  publication-title: Am. J. Gastroenterol.
  doi: 10.1038/ajg.2016.306
– volume: 32
  start-page: 235
  year: 2022
  ident: ref_87
  article-title: Pharmacogenetic Analysis of Canonical versus Noncanonical Pathway of NF-kB in Crohn’s Disease Patients under Anti-Tumor Necrosis Factor-alfa Treatment
  publication-title: Pharmacogenet. Genom.
  doi: 10.1097/FPC.0000000000000471
– ident: ref_7
  doi: 10.3390/ijms23136966
– volume: 133
  start-page: 16461
  year: 2023
  ident: ref_26
  article-title: Association of the ILR1 and FAS Genes Variants with a Primary Non-Response to Anti-TNF Therapy in Crohn’s Disease Patients
  publication-title: Pol. Arch. Intern. Med.
– volume: 152
  start-page: S380
  year: 2017
  ident: ref_52
  article-title: UBE2L3, ANCA, ASCA, and CBIR1 Are Associated with Mechanisms of Non-Response to Anti-TNF in IBD Patients with Adequate Drug Levels
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(17)31514-7
– volume: 71–72
  start-page: 1
  year: 2023
  ident: ref_12
  article-title: Recent Advances in the Treatment of IBD: Targets, Mechanisms and Related Therapies
  publication-title: Cytokine Growth Factor Rev.
  doi: 10.1016/j.cytogfr.2023.07.001
– volume: 4
  start-page: 1108
  year: 2020
  ident: ref_93
  article-title: TL1A (TNFSF15) Genotype Affects the Long-Term Therapeutic Outcomes of Anti-TNF Antibodies for Crohn’s Disease Patients
  publication-title: JGH Open
  doi: 10.1002/jgh3.12398
– volume: 26
  start-page: 680
  year: 2019
  ident: ref_74
  article-title: Cross Disease Pharmacogenetic Analysis Predicting Anti-TNF Response Identifies SNPs Predicting Adalimumab Response in Crohn’s Disease Patients
  publication-title: Eur. J. Hum. Genet.
– volume: 14
  start-page: 2184
  year: 2021
  ident: ref_38
  article-title: Pharmacogenetic Variants of Infliximab Response in Young Patients with Inflammatory Bowel Disease
  publication-title: Clin. Transl. Sci.
  doi: 10.1111/cts.13075
– ident: ref_116
  doi: 10.3390/ijms25073717
– volume: 116
  start-page: S317
  year: 2021
  ident: ref_105
  article-title: Early Proactive Ifx Dose Optimization Negates the Impact of HLA-DQA1*05 on Anti-Drug Antibody Formation in Inflammatory Bowel Diseases
  publication-title: Am. J. Gastroenterol.
  doi: 10.14309/01.ajg.0000776332.13982.cb
– volume: 17
  start-page: 419
  year: 2019
  ident: ref_2
  article-title: Integrating Omics for a Better Understanding of Inflammatory Bowel Disease: A Step towards Personalized Medicine
  publication-title: J. Transl. Med.
  doi: 10.1186/s12967-019-02174-1
– volume: 10
  start-page: CD000067
  year: 2015
  ident: ref_3
  article-title: Azathioprine or 6-Mercaptopurine for Maintenance of Remission in Crohn’s Disease
  publication-title: Cochrane Database Syst. Rev.
– volume: 69
  start-page: 431
  year: 2013
  ident: ref_30
  article-title: Influence of Polymorphisms and TNF and IL1beta Serum Concentration on the Infliximab Response in Crohn’s Disease and Ulcerative Colitis
  publication-title: Eur. J. Clin. Pharmacol.
  doi: 10.1007/s00228-012-1389-0
– volume: 102
  start-page: 591
  year: 2010
  ident: ref_103
  article-title: NOD2, CD14 and TLR4 Mutations Do Not Influence Response to Adalimumab in Patients with Crohn’s Disease: A Preliminary Report
  publication-title: Rev. Esp. Enferm. Dig.
– volume: 372
  start-page: n71
  year: 2021
  ident: ref_16
  article-title: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
  publication-title: BMJ
  doi: 10.1136/bmj.n71
– ident: ref_13
  doi: 10.3390/jcm12227132
– volume: 24
  start-page: 1840
  year: 2018
  ident: ref_33
  article-title: Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis
  publication-title: Inflamm. Bowel Dis.
  doi: 10.1093/ibd/izy083
– volume: 18
  start-page: 597
  year: 2004
  ident: ref_115
  article-title: Pharmacogenetics of Inflammatory Bowel Disease
  publication-title: Best Pr. Res. Clin. Gastroenterol.
– volume: 9
  start-page: 427
  year: 2021
  ident: ref_24
  article-title: Multi-Alleles Predict Primary Non-Response to Infliximab Therapy in Crohn’s Disease
  publication-title: Gastroenterol. Rep.
  doi: 10.1093/gastro/goaa070
– ident: ref_118
  doi: 10.3390/ijms25115793
– volume: 13
  start-page: 1036
  year: 2019
  ident: ref_78
  article-title: Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients with Inflammatory Bowel Disease
  publication-title: J. Crohn’s Colitis
  doi: 10.1093/ecco-jcc/jjz017
– volume: 12
  start-page: 797
  year: 2018
  ident: ref_15
  article-title: How to Predict Response to Anti-Tumour Necrosis Factor Agents in Inflammatory Bowel Disease
  publication-title: Expert Rev. Gastroenterol. Hepatol.
  doi: 10.1080/17474124.2018.1494573
– volume: 16
  start-page: 727
  year: 2006
  ident: ref_101
  article-title: The TNF/ADAM 17 System: Implication of an ADAM 17 Haplotype in the Clinical Response to Infliximab in Crohn’s Disease
  publication-title: Pharmacogenet. Genom.
  doi: 10.1097/01.fpc.0000230117.26581.a4
– volume: 15
  start-page: S301
  year: 2021
  ident: ref_68
  article-title: P264 Impact of the HLA-DQ1*05 Alelle on the Initial Response to Infliximab in Patients with Inflammatory Bowel Disease
  publication-title: J. Crohn’s Colitis
  doi: 10.1093/ecco-jcc/jjab076.390
– volume: 62
  start-page: 733
  year: 2014
  ident: ref_92
  article-title: A Novel SNP in Tnfrsf1b Is Associated with Response to Anti-TNF Therapy in Inflammatory Bowel Disease Patients
  publication-title: J. Investig. Med.
– volume: 58
  start-page: I114
  year: 1999
  ident: ref_6
  article-title: Anti-TNF Antibody Treatment of Crohn’s Disease
  publication-title: Ann. Rheum. Dis.
  doi: 10.1136/ard.58.2008.i114
– volume: 162
  start-page: S-801
  year: 2022
  ident: ref_71
  article-title: A serogenetic panel combining poor prognostic factors of pharmacokinetic and pharmacogenetic origin impacts time to remission during infliximab therapy in inflammatory bowel diseases
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(22)61892-4
– ident: ref_44
  doi: 10.3389/fimmu.2024.1342477
– ident: ref_25
  doi: 10.3390/genes14020452
– volume: 20
  start-page: 3609
  year: 2014
  ident: ref_95
  article-title: Association of Rs1568885, Rs1813443 and Rs4411591 Polymorphisms with Anti-TNF Medication Response in Greek Patients with Crohn’s Disease
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v20.i13.3609
– volume: 42
  start-page: 16
  year: 2007
  ident: ref_14
  article-title: Inflammatory Bowel Disease: Past, Present, and Future
  publication-title: J. Gastroenterol.
  doi: 10.1007/s00535-006-1995-7
– volume: 19
  start-page: 547
  year: 2019
  ident: ref_53
  article-title: Genetic Association between CD96 Locus and Immunogenicity to Anti-TNF Therapy in Crohn’s Disease
  publication-title: Pharmacogenom. J.
  doi: 10.1038/s41397-019-0090-4
– ident: ref_47
  doi: 10.1016/j.biopha.2023.114225
– volume: 116
  start-page: S458
  year: 2021
  ident: ref_54
  article-title: Pharmacogene CYP1A2*1F Polymorphism Lowers Anti-Tnf (Infliximab) Response in Inflammatory Bowel Disease Patients
  publication-title: Am. J. Gastroenterol.
  doi: 10.14309/01.ajg.0000777364.76967.26
– volume: 41
  start-page: 63
  year: 2014
  ident: ref_89
  article-title: Genetic Polymorphisms of Tumour Necrosis Factor Alpha (TNF-α) Promoter Gene and Response to TNF-α Inhibitors in Spanish Patients with Inflammatory Bowel Disease
  publication-title: Int. J. Immunogenet.
  doi: 10.1111/iji.12059
– volume: 19
  start-page: 339
  year: 2015
  ident: ref_102
  article-title: Association of Survivin Promoter Polymorphisms with Inflammatory Bowel Disease and Response to Antitumor Necrosis Factor Therapy
  publication-title: Genet Test Mol Biomark.
  doi: 10.1089/gtmb.2015.0036
– volume: 34
  start-page: 2118
  year: 2019
  ident: ref_94
  article-title: Association of TRAP1 with Infliximab-Induced Mucosal Healing in Crohn’s Disease
  publication-title: J. Gastroenterol. Hepatol. Aust.
  doi: 10.1111/jgh.14696
– volume: 54
  start-page: 476
  year: 2016
  ident: ref_66
  article-title: Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn’s Disease Patients
  publication-title: Biochem. Genet.
  doi: 10.1007/s10528-016-9734-0
– volume: 10
  start-page: S479
  year: 2016
  ident: ref_76
  article-title: Impact of the Rs1143634 Polymorphism in the Gene Coding for IL1beta on Pharmacokinetic of Infliximab in Inflammatory Bowel Disease Patients
  publication-title: J. Crohn’s Colitis
– ident: ref_61
  doi: 10.3390/pharmaceutics13010077
– ident: ref_39
  doi: 10.3389/fphar.2023.1096816
– ident: ref_27
  doi: 10.3389/fphar.2020.01207
– volume: 15
  start-page: 10
  year: 2018
  ident: ref_40
  article-title: A FCGR3A Polymorphism Predicts Anti-Drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated with Anti-TNF
  publication-title: Int. J. Med. Sci.
  doi: 10.7150/ijms.22812
– volume: 14
  start-page: 1316
  year: 2020
  ident: ref_4
  article-title: The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease
  publication-title: J. Crohn’s Colitis
  doi: 10.1093/ecco-jcc/jjaa053
– volume: 120
  start-page: 1347
  year: 2001
  ident: ref_80
  article-title: ANCA Pattern and LTA Haplotype Relationship to Clinical Responses to Anti-TNF Antibody Treatment in Crohn’s Disease
  publication-title: Gastroenterology
  doi: 10.1053/gast.2001.23966
– volume: 50
  start-page: 758
  year: 2015
  ident: ref_83
  article-title: Anti-TNF-Alpha Loss of Response Is Associated with a Decreased Percentage of FoxP3+ T Cells and a Variant NOD2 Genotype in Patients with Crohn’s Disease
  publication-title: J. Gastroenterol.
  doi: 10.1007/s00535-014-1020-5
– volume: 30
  start-page: 241
  year: 2015
  ident: ref_98
  article-title: NOD-Like Receptors: Guardians of Intestinal Mucosal Barriers
  publication-title: Physiology
  doi: 10.1152/physiol.00025.2014
– volume: 18
  start-page: 87
  year: 2018
  ident: ref_73
  article-title: Genetically Determined High Activity of IL-12 and IL-18 in Ulcerative Colitis and TLR5 in Crohns Disease Were Associated with Non-Response to Anti-TNF Therapy
  publication-title: Pharmacogenom. J.
  doi: 10.1038/tpj.2016.84
– volume: 37
  start-page: 818
  year: 2002
  ident: ref_114
  article-title: A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation before Treatment but Not with -308 TNF Gene Polymorphism
  publication-title: Scand. J. Gastroenterol.
  doi: 10.1080/gas.37.7.818.824
– volume: 20
  start-page: 303
  year: 2004
  ident: ref_91
  article-title: Tumour Necrosis Factor-Alpha Receptor 1 and 2 Polymorphisms in Inflammatory Bowel Disease and Their Association with Response to Infliximab
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2004.01946.x
– volume: 14
  start-page: 526
  year: 2014
  ident: ref_18
  article-title: Associations between Functional Polymorphisms in the NFKB Signaling Pathway and Response to Anti-TNF Treatment in Danish Patients with Inflammatory Bowel Disease
  publication-title: Pharmacogenom. J.
  doi: 10.1038/tpj.2014.19
– volume: 23
  start-page: 4958
  year: 2017
  ident: ref_29
  article-title: Genetic Polymorphisms Predict Response to Anti-Tumor Necrosis Factor Treatment in Crohn’s Disease
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v23.i27.4958
– volume: 23
  start-page: A182
  year: 2016
  ident: ref_77
  article-title: Impact of the RS1143634 Polymorphism of Interleukin 1b on Infliximab Exposure in Crohn’s Disease and Ulcerative Colitis Patients
  publication-title: Eur. J. Hosp. Pharm.
– volume: 123
  start-page: 106
  year: 2002
  ident: ref_113
  article-title: NOD2/CARD15 Does Not Influence Response to Infliximab in Crohn’s Disease
  publication-title: Gastroenterology
  doi: 10.1053/gast.2002.34172
– volume: 27
  start-page: 765
  year: 2008
  ident: ref_90
  article-title: Genetic Polymorphisms of Tumour Necrosis Factor Receptor Superfamily 1A and 1B Affect Responses to Infliximab in Japanese Patients with Crohn’s Disease
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2008.03630.x
– volume: 22
  start-page: 613
  year: 2005
  ident: ref_28
  article-title: Polymorphisms in Apoptosis Genes Predict Response to Infliximab Therapy in Luminal and Fistulizing Crohn’s Disease
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2005.02635.x
– volume: 93
  start-page: 182
  year: 2016
  ident: ref_86
  article-title: The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort
  publication-title: Digestion
  doi: 10.1159/000444479
– volume: 149
  start-page: 104478
  year: 2019
  ident: ref_34
  article-title: Genetic Predictors of Long-Term Response and Trough Levels of Infliximab in Crohn’s Disease
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2019.104478
– volume: 22
  start-page: 1129
  year: 2005
  ident: ref_109
  article-title: Multidrug Resistance 1 Gene Polymorphisms Are Not Associated with Inflammatory Bowel Disease and Response to Therapy in Italian Patients
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2005.02701.x
– volume: 111
  start-page: 1816
  year: 2016
  ident: ref_31
  article-title: Genetic Markers Predict Primary Non-Response and Durable Response to Anti-TNF Biologic Therapies in Crohn’s Disease
  publication-title: Am. J. Gastroenterol.
  doi: 10.1038/ajg.2016.408
– volume: 51
  start-page: 356
  year: 2020
  ident: ref_45
  article-title: HLADQA1*05 Genotype Predicts Anti-Drug Antibody Formation and Loss of Response during Infliximab Therapy for Inflammatory Bowel Disease
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/apt.15563
– volume: 29
  start-page: 1586
  year: 2023
  ident: ref_69
  article-title: Influence of HLADQA1*05 Genotype in Adults with Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study
  publication-title: Inflamm. Bowel Dis.
  doi: 10.1093/ibd/izac259
– volume: 31
  start-page: 356
  year: 2020
  ident: ref_96
  article-title: The Role of FAS Gene Variants in Inflammatory Bowel Disease
  publication-title: Turk. J. Gastroenterol.
  doi: 10.5152/tjg.2020.19436
– volume: 71
  start-page: 508
  year: 2020
  ident: ref_19
  article-title: Genetic Predictors of Long-Term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease
  publication-title: J. Pediatr. Gastroenterol. Nutr.
  doi: 10.1097/MPG.0000000000002840
– volume: 9
  start-page: 513
  year: 2016
  ident: ref_11
  article-title: Predicting Durable Response or Resistance to Antitumor Necrosis Factor Therapy in Inflammatory Bowel Disease
  publication-title: Ther. Adv. Gastroenterol.
  doi: 10.1177/1756283X16638833
– volume: 12
  start-page: 509
  year: 2002
  ident: ref_112
  article-title: Response to Infliximab Treatment in Crohn’s Disease Is Not Associated with Mutations in the CARD15 (NOD2) Gene: An Analysis in 534 Patients from Two Multicenter, Prospective GCP-Level Trials
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-200210000-00002
– volume: 87
  start-page: 447
  year: 2021
  ident: ref_82
  article-title: Pharmacogenetics of Trough Serum Anti-TNF Levels in Paediatric Inflammatory Bowel Disease
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/bcp.14400
– ident: ref_70
  doi: 10.3390/ijms24021797
– volume: 12
  start-page: 205
  year: 2015
  ident: ref_1
  article-title: Epidemiology and Risk Factors for IBD
  publication-title: Nat. Rev. Gastroenterol. Hepatol.
  doi: 10.1038/nrgastro.2015.34
– volume: 11
  start-page: 1187
  year: 2005
  ident: ref_72
  article-title: IBD5 Polymorphisms in Inflammatory Bowel Disease: Association with Response to Infliximab
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v11.i8.1187
– ident: ref_75
  doi: 10.1155/2015/416838
– ident: ref_85
  doi: 10.3390/genes12060866
– volume: 36
  start-page: 650
  year: 2012
  ident: ref_22
  article-title: Genetic Polymorphisms of Tumour Necrosis Factor Receptor Superfamily 1b and Fas Ligand Are Associated with Clinical Efficacy and/or Acute Severe Infusion Reactions to Infliximab in Crohn’s Disease
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/apt.12010
– volume: 87
  start-page: S19
  year: 2010
  ident: ref_81
  article-title: Prediction of Anti-TNF Response in Inflammatory Bowel Disease (IBD) Patients Using a Haplotype TAG-SNP (htSNP) Method
  publication-title: Clin. Pharmacol. Ther.
– volume: 29
  start-page: 437
  year: 2023
  ident: ref_63
  article-title: Decreased Infliximab Concentrations in Patients with Inflammatory Bowel Disease Who Carry a Variable Number Tandem Repeat Polymorphism in the Neonatal Fc Receptor or Variant HLADQA1*05G>A Genotype
  publication-title: Inflamm. Bowel Dis.
  doi: 10.1093/ibd/izac188
– volume: 24
  start-page: 35
  year: 2011
  ident: ref_97
  article-title: Association of TNF and FcγRΙΙΙA Gene Polymorphisms with Differential Response to Infliximab in a Greek Cohort of Crohn’s Disease Patients
  publication-title: Ann. Gastroenterol.
– volume: 19
  start-page: 511
  year: 2004
  ident: ref_56
  article-title: Association between Polymorphism in IgG Fc Receptor IIIa Coding Gene and Biological Response to Infliximab in Crohn’s Disease
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2004.01871.x
– volume: 16
  start-page: 911
  year: 2006
  ident: ref_57
  article-title: Polymorphism in IgG Fc Receptor Gene FCGR3A and Response to Infliximab in Crohn’s Disease: A Subanalysis of the ACCENT I Study
  publication-title: Pharmacogenet. Genom.
  doi: 10.1097/01.fpc.0000230421.12844.fd
– volume: 20
  start-page: 296
  year: 2016
  ident: ref_50
  article-title: A Prospective Pharmacogenomic Study of Crohn’s Disease Patients during Routine Therapy with Anti-TNF Drug Adalimumab: Contribution of ATG5, NFKB1, and CRP Genes to Pharmacodynamic Variability
  publication-title: OMICS J. Integr. Biol.
  doi: 10.1089/omi.2016.0005
– volume: 14
  start-page: S574
  year: 2020
  ident: ref_67
  article-title: P711 Carriage of the HLA-DQA1*05 Allele Is Associated with a High Risk of Loss of Response to Adalimumab in Patients with Crohn’s Disease
  publication-title: J. Crohn’s Colitis
  doi: 10.1093/ecco-jcc/jjz203.839
– ident: ref_41
  doi: 10.3389/fped.2021.744599
– volume: 23
  start-page: 112
  year: 2023
  ident: ref_46
  article-title: One Year of Experience with Combined Pharmacokinetic/Pharmacogenetic Monitoring of Anti-TNF Alpha Agents: A Retrospective Study
  publication-title: Pharmacogenom. J.
  doi: 10.1038/s41397-023-00304-z
– volume: 16
  start-page: 37
  year: 2006
  ident: ref_104
  article-title: No Association between C-Reactive Protein Gene Polymorphisms and Decrease of C-Reactive Protein Serum Concentration after Infliximab Treatment in Crohn’s Disease
  publication-title: Pharmacogenet. Genom.
  doi: 10.1097/01.fpc.0000182776.57437.d8
– volume: 19
  start-page: 678
  year: 2018
  ident: ref_37
  article-title: Mutations in the NOD2 Gene Are Associated with a Specific Phenotype and Lower Anti-Tumor Necrosis Factor Trough Levels in Crohn’s Disease
  publication-title: J. Dig. Dis.
  doi: 10.1111/1751-2980.12677
– volume: 19
  start-page: 383
  year: 2009
  ident: ref_107
  article-title: IgG1 Heavy Chain-Coding Gene Polymorphism (G1m Allotypes) and Development of Antibodies-to-Infliximab
  publication-title: Pharmacogenet. Genom.
  doi: 10.1097/FPC.0b013e32832a06bf
– volume: 16
  start-page: 191
  year: 2015
  ident: ref_17
  article-title: Genetic Polymorphism in ATG16L1 Gene Influences the Response to Adalimumab in Crohn’s Disease Patients
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.14.172
– volume: 4
  start-page: CD000543
  year: 2016
  ident: ref_5
  article-title: Oral 5-Aminosalicylic Acid for Induction of Remission in Ulcerative Colitis
  publication-title: Cochrane Database Syst. Rev.
– volume: 68
  start-page: 11
  year: 2019
  ident: ref_32
  article-title: Pharmacogenetics of Anti-TNF Therapy in Paediatric Crohns’ Disease and Ulcerative Colitis. Comparison with Adults
  publication-title: J. Pediatr. Gastroenterol. Nutr.
– volume: 15
  start-page: 248
  year: 2017
  ident: ref_49
  article-title: Genetic Polymorphism in ATG16L1 Gene Is Associated with Adalimumab Use in Inflammatory Bowel Disease
  publication-title: J. Transl. Med.
  doi: 10.1186/s12967-017-1355-9
– volume: 57
  start-page: 879
  year: 2012
  ident: ref_84
  article-title: NOD2 Polymorphism Predicts Response to Treatment in Crohn’s Disease-First Steps to a Personalized Therapy
  publication-title: Dig. Dis. Sci.
  doi: 10.1007/s10620-011-1977-3
– volume: 42
  start-page: 726
  year: 2007
  ident: ref_100
  article-title: ATP-Binding Cassette Transporter ABCG2 (BCRP) and ABCB1 (MDR1) Variants Are Not Associated with Disease Susceptibility, Disease Phenotype Response to Medical Therapy or Need for Surgeryin Hungarian Patients with Inflammatory Bowel Diseases
  publication-title: Scand. J. Gastroenterol.
  doi: 10.1080/00365520601101559
– volume: 49
  start-page: 890
  year: 2019
  ident: ref_20
  article-title: Polymorphisms in the NFkB, TNF-Alpha, IL-1beta, and IL-18 Pathways Are Associated with Response to Anti-TNF Therapy in Danish Patients with Inflammatory Bowel Disease
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/apt.15187
– volume: 18
  start-page: 5058
  year: 2012
  ident: ref_106
  article-title: Crohn’s Disease Genotypes of Patients in Remission vs Relapses after Infliximab Discontinuation
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v18.i36.5058
– volume: 25
  start-page: 1896
  year: 2019
  ident: ref_8
  article-title: The Role of Early Biologic Therapy in Inflammatory Bowel Disease
  publication-title: Inflamm. Bowel Dis.
  doi: 10.1093/ibd/izz059
SSID ssj0023259
Score 2.4419274
SecondaryResourceType review_article
Snippet Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders influenced by microbial, environmental, genetic, and immune factors. The introduction of...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 1760
SubjectTerms Analysis
Biological Factors - therapeutic use
Clinical outcomes
Crohn's disease
Diseases
Ethnicity
Genes
Genetic markers
Genotype & phenotype
Humans
Inflammatory bowel disease
Inflammatory Bowel Diseases - drug therapy
Inflammatory Bowel Diseases - genetics
Kinases
Medical research
Medical Subject Headings-MeSH
Pharmacogenetics
Pharmacogenetics - methods
Polymorphism
Precision Medicine
Review
Spain
Systematic review
Tofacitinib
Toxicity
Treatment Outcome
Tumor necrosis factor-TNF
SummonAdditionalLinks – databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LbtQw0IIiJC6I8gwUZCQQJ6vxehzHXKqlsBQkEAIq9RYltqMuoklht0L8fWfsbLrhwNnjxJoZz8PzYuxFq2TQNXgBZeMEtFKL2oEV4KVvNAoHFSfPffpcHB3DxxN9Mjy4rYa0yo1MjILa947eyPdxD-pCrSA_OP8laGoURVeHERrX2Q05Q11LleKL96PDpWZxWJpEHSQKbYuU-K7Qzd9f_jhboSkP0sTmlFcq6V_BvKWZplmTW2pocYfdHuxHPk8E32XXQneX3UwTJf_eY_7L0Ioa-YLKE1d82fGvKQ828HXPEyRRhs-pqioCfOhaZIyzGHDnb_o_4Sd_mwI3r_mcfxubPfMUSbjPjhfvvh8eiWGQgnCgzFo0M11SEFeWNapnNPKUl0S6QrUQvC4LCNqXqqkN3n_lc2U8BeDaAMY3uXHqAdvp-i48Yry12pvaSBtsA3nbNhq8tQ5cQFsu1GXGXm5wWZ2nfhkV-hmE82ob5xl7RYiu6BohNl09VAPgX6ghVTWPJb-A4idjexNIZH83Xd6Qqhqu36q6YpaMPR-XaSellHWhv0gwylgL-ImHibLjiSGPvdFUxsoJzUcAaso9XemWp7E5NzpsaKEZePz_cz1ht2Y0SZhGy9g9trP-fRGeonmzbp5FHr4EMxv5kA
  priority: 102
  providerName: ProQuest
Title Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review
URI https://www.ncbi.nlm.nih.gov/pubmed/40004223
https://www.proquest.com/docview/3171025340
https://www.proquest.com/docview/3171379941
https://pubmed.ncbi.nlm.nih.gov/PMC11855474
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED_xoUm8oLENKIPKk4b2lNHU5zqehFBhdGwSCLFV6luUxI7WCVKgRRv__e7iNGpgT3vJi89JdHf2_U73BfA-l6FTCdoAozQLMA9VkGRoArShTRVdDrKcPHd-0Tsb4reRGi3BfNpoxcDpP107nic1vL_--Ofu8YgO_CF7nOSyH4x_3UwJlmOoe-S8r5aRIk7iwzqeQLBBGZ_2_mxHwyA9vZYX7FIzZ3LBCA1ewnqFHkXfi3sDllzxCl74eZKPr8FeVo2oSSu4OHEqxoW48lmwTswmwlOyXESfa6pKgq9FTmpxU4bbxfHkt7sWn33Y5pPoi-91q2fh4whvYDg4_XFyFlRjFIIMpZ4FaVdFHMINo4SMM0E8aUMWXE_m6KyKeuiUjWSaaDr90nakthx-yx1qm3Z0JjdhpZgUbhtEbpTViQ6NMyl28jxVaI3JMHOE5FwStWB_zsv41nfLiMnLYJ7HizxvwQdmdMxiJW5mSVULQF_hdlRxvyz4Rbp8WrDboCTlz5rLc1HFc92JSb0INimJ9J139TLv5ISywk0ePI3UxiC9YstLtv5j7JSd0WQLoobMawJuyd1cKcY_y9bc5K4RPtO48_9b38Jal2cM89AZswsrs_sHt0fAZ5a2YVmPND2jwZc2rB6fXlxetdkUqXap7X8Be3oKog
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0CpFCC6IN4ECRqLiFDWJx3GMhNBCWXbpQwhaqbc0iR2xiCaF3arqT_GNzNhJusuBW8-eOM48PDOZF2OvahFbWYAJISurEOpYhkUFOgQTm1Li5SDc5Lm9_XRyCJ-P5NEa-9PXwlBaZX8nuovatBX9I9_CZ1AXSgHRu9NfIU2NouhqP0LDs8WOvThHl23-drqN9N1MkvHHgw-TsJsqEFYg1CIsE5lRRDPOCtRVaPEIE9N3pKIGa2SWgpUmE2WhUBiEiYQyFI2qLShTRqoSuO81dh2EEJRCmI0_DQ6eSNxwthh1XphKnfpEeyF0tDX7cTJH1wFi5ZphXqrAfxXBkiZczdJcUnvjO-x2Z6_ykWewu2zNNvfYDT_B8uI-M1-61tfIh1QOOeezhn_1ebeWL1ruIYkT-IiquBzAtKmREU9cgJ-_b8_tT77tA0Vv-Ih_G5pLcx-5eMAOrwTFD9l60zb2MeO1lkYVKtZWlxDVdSnBaF1BZdF2tEUWsM0el_mp78-Ro19DOM-XcR6w14TonMQWsVkVXfUBvoUaYOUjV2IMeN0FbGMFEsWtWl3uSZV34j7PL5kzYC-HZXqSUtga2555GKG0BtzikafscGKIXC82EbBsheYDADUBX11pZt9dM3B0ENEiVPDk_-d6wW5ODvZ2893p_s5TdiuhKcY01kZvsPXF7zP7DE2rRfnc8TNnx1ctQH8BPvo1CQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQwcFSKQFwQbwIFjETFKdoktuMYCaGFZdWlUFVApb2FJHbUrWhS2K2q_hpfx4yd7IMDt549cZx5eGYyL4BXNY-tLIQJRVZWoahjGRaV0KEwsSklXg7cTZ77cpDuHYlPUzndgj99LQylVfZ3oruoTVvRP_IBPoO6UHIRDeouLeJwNH539iukCVIUae3HaXgW2beXF-i-zd9ORkjr3SQZf_z-YS_sJgyEleBqEZaJzCi6GWcF6i20friJ6ZtSXgtrZJYKK03Gy0KhYHATcWUoMlVboUwZqYrjvtfguuK4B8qSmq6cPZ64QW0x6r8wlTr1Sfec62gwOzmdoxshYuUaY67U4b9KYU0rbmZsrqnA8R243dmubOiZ7S5s2eYe3PDTLC_vgzns2mAjT1Jp5JzNGvbV5-BatmiZhySuYEOq6HIAk6ZGpjx1wX72vr2wP9nIB43esCH7tmw0zXwU4wEcXQmKH8J20zb2MbBaS6MKFWurSxHVdSmF0boSlUU70hZZALs9LvMz36sjRx-HcJ6v4zyA14TonEQYsVkVXSUCvoWaYeVDV24s8OoLYGcDEkWv2lzuSZV3oj_PV4wawMvlMj1J6WyNbc89DFdaC9zikafs8sQicn3ZeADZBs2XANQQfHOlmR27xuDoLKJ1qMST_5_rBdxE0ck_Tw72n8KthAYa04QbvQPbi9_n9hlaWYvyuWNnBj-uWn7-Ao54OTw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacogenetics+in+Response+to+Biological+Agents+in+Inflammatory+Bowel+Disease%3A+A+Systematic+Review&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Ballesta-L%C3%B3pez%2C+Octavio&rft.au=Gil-Candel%2C+Mayte&rft.au=Centelles-Oria%2C+Mar%C3%ADa&rft.au=Meg%C3%ADas-Vericat%2C+Juan+Eduardo&rft.date=2025-02-19&rft.pub=MDPI&rft.eissn=1422-0067&rft.volume=26&rft.issue=4&rft_id=info:doi/10.3390%2Fijms26041760&rft.externalDocID=PMC11855474
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon